PBA
AGIO icon

Paradigm Biocapital Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Paradigm Biocapital Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,673,555
Closed -$107M – 32
2025
Q3 		$107M Buy
2,673,555
+1,531,044
+134% +$57.6M 3.05% 9
2025
Q2 		$38M Buy
+1,142,511
New +$34.6M 1.62% 20
2025
Q1 		– Sell
-276,439
Closed -$9.08M – 29
2024
Q4 		$9.08M Buy
+276,439
New +$13M 0.32% 28
2024
Q2 		– Sell
-400,000
Closed -$11.7M – 36
2024
Q1 		$11.7M Buy
+400,000
New +$10.7M 0.41% 31

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Paradigm Biocapital Advisors's AGIO Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 2,673,555 shares — an estimated $107M sold.

Paradigm Biocapital Advisors first reported a position in AGIO in Q1 2024 and held it in 4 quarters. The position peaked at $107M in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • Paradigm Biocapital Advisors reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,673,555 Agios Pharmaceuticals shares in Q4 2025, an estimated $107M.
  • Paradigm Biocapital Advisors first reported a position in Agios Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's Agios Pharmaceuticals position peaked at $107M in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.